8-K: OrthoPediatrics Corp. Announces Record Third Quarter Revenue and Raises Full Year Guidance

OrthoPediatrics Corp. reported a 37% year-over-year increase in third-quarter revenue and raised its full-year revenue guidance.

Summary

• OrthoPediatrics Corp. announced its financial results for the third quarter ended September 30, 2024, achieving record revenue of $54.6 million, a 37% increase compared to the same period last year.
• Domestic revenue grew by 45% to $42.7 million, while international revenue increased by 12% to $11.9 million.
• The company experienced significant growth across all business segments, with Trauma and Deformity revenue up 31%, Scoliosis revenue up 52%, and Sports Medicine/Other revenue up 50%.
• Gross profit for the quarter was $40.1 million, a 29% increase year-over-year, although the gross profit margin decreased to 73% from 77% due to product mix changes.
• Operating expenses increased by 29% to $45.6 million, primarily due to the acquisition of Boston O&P and increased personnel costs.
• The company reported a net loss of $7.9 million, compared to a net loss of $4.6 million in the same quarter last year, with a loss per share of $0.34.
• Adjusted EBITDA for the quarter was $4.0 million, compared to $3.6 million in the third quarter of 2023.
• OrthoPediatrics increased its full-year 2024 revenue guidance to $202 million to $204 million, representing a 36% to 37% growth over the previous year.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with strong revenue growth and increased guidance, but the increased net loss and decreased gross margin temper the overall sentiment.

Positives

• The company experienced strong revenue growth across all business segments.
• OrthoPediatrics increased its full-year revenue guidance.
• The launch of the Enabling Technologies Division indicates a focus on future growth and innovation.
• The company helped a record number of children in the third quarter.
• The company saw a significant increase in Scoliosis revenue.

Negatives

• The company reported a net loss of $7.9 million for the quarter, which is higher than the $4.6 million loss in the same period last year.
• Gross profit margin decreased from 77% to 73% due to changes in product mix.
• Total operating expenses increased by 29% due to the acquisition of Boston O&P and increased personnel costs.
• Total other expense increased significantly due to a one-time refinancing expense of $3.2 million.

Risks

• The company's net loss increased compared to the same period last year.
• The decrease in gross profit margin could impact future profitability.
• Increased operating expenses may continue to affect the bottom line.
• The company's future performance is subject to risks and uncertainties, including the impact of health emergencies.

Future Outlook

The company is confident in its performance for the remainder of 2024 and expects to continue its growth while maintaining healthy gross margins and generating substantial EBITDA. The company increased its full-year 2024 revenue guidance to $202 million to $204 million.

Management Comments

• David Bailey, President & CEO of OrthoPediatrics, stated that the third quarter results represent another strong performance and that the company continued its positive momentum and executed its strategic initiatives.
• He also mentioned that the company saw strength across all business segments and is confident in the remainder of 2024 and the long-term outlook.

Industry Context

The announcement reflects a positive trend in the pediatric orthopedics market, with OrthoPediatrics demonstrating strong growth in a specialized sector. The launch of the Enabling Technologies Division also indicates a move towards incorporating digital health and advanced technology, which is a growing trend in the medical device industry.

Comparison to Industry Standards

• While specific competitor data is not provided in the document, OrthoPediatrics' 37% revenue growth in the third quarter is significant and suggests a strong market position compared to industry averages.
• The company's focus on pediatric orthopedics gives it a niche advantage, but it also faces competition from larger medical device companies that may have broader product portfolios.
• The 52% growth in Scoliosis revenue is particularly noteworthy and may indicate a competitive advantage in this specific area.
• The decrease in gross margin from 77% to 73% is a point of concern and should be monitored against industry benchmarks.

Stakeholder Impact

• Shareholders will likely react positively to the increased revenue guidance and strong growth, but may be concerned about the increased net loss.
• Employees may benefit from the company's growth and expansion.
• Customers, including hospitals and surgeons, will have access to a wider range of pediatric orthopedic products and services.
• Suppliers may see increased demand for their products and services.

Next Steps

• OrthoPediatrics will host a conference call on November 7, 2024, to discuss the results.
• The company will continue to focus on executing its strategic initiatives and growing its market share.

Key Dates

Keywords

OrthoPediatrics, pediatric orthopedics, revenue, financial results, EBITDA, Scoliosis, Trauma and Deformity, Sports Medicine, medical devices, growth, guidance